United Therapeutics Corporation (NASDAQ: UTHR) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both biotechnology & medical research – nec companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
This is a breakdown of recent ratings and recommmendations for United Therapeutics Corporation and Sunesis Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|United Therapeutics Corporation||3||6||2||0||1.91|
United Therapeutics Corporation currently has a consensus target price of $135.50, indicating a potential upside of 11.41%. Sunesis Pharmaceuticals has a consensus target price of $3.00, indicating a potential upside of 8.30%. Given United Therapeutics Corporation’s higher probable upside, analysts plainly believe United Therapeutics Corporation is more favorable than Sunesis Pharmaceuticals.
Risk & Volatility
United Therapeutics Corporation has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Institutional & Insider Ownership
56.4% of Sunesis Pharmaceuticals shares are owned by institutional investors. 7.8% of United Therapeutics Corporation shares are owned by company insiders. Comparatively, 10.2% of Sunesis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares United Therapeutics Corporation and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|United Therapeutics Corporation||30.50%||26.24%||19.37%|
Earnings & Valuation
This table compares United Therapeutics Corporation and Sunesis Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|United Therapeutics Corporation||$1.60 billion||3.29||$713.70 million||$11.34||10.72|
|Sunesis Pharmaceuticals||$2.54 million||37.35||-$38.02 million||($1.75)||-1.58|
United Therapeutics Corporation has higher revenue and earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics Corporation, indicating that it is currently the more affordable of the two stocks.
United Therapeutics Corporation beats Sunesis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.